Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients.

Portal D, Hofstetter L, Eshed I, Dan-Lantsman C, Sella T, Urban D, Onn A, Bar J, Segal G.

Cancer Manag Res. 2019 Apr 1;11:2579-2588. doi: 10.2147/CMAR.S195869. eCollection 2019.

2.

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.

Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group.

Clin Lung Cancer. 2019 Apr 5. pii: S1525-7304(19)30080-4. doi: 10.1016/j.cllc.2019.03.007. [Epub ahead of print]

PMID:
31060855
3.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Bra├▒a I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R.

Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.

PMID:
31011205
4.

Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes.

Appel S, Bar J, Ben-Nun A, Perelman M, Alezra D, Urban D, Ben-Ayun M, Honig N, Ofek E, Katzman T, Onn A, Chatterji S, Dubinski S, Tsvang L, Felder S, Kraitman J, Haisraely O, Rabin Alezra T, Lieberman S, Marom EM, Golan N, Simansky D, Symon Z, Lawrence YR.

Br J Radiol. 2019 May;92(1097):20180960. doi: 10.1259/bjr.20180960. Epub 2019 Apr 1.

PMID:
30864828
5.

Short tandem repeat stutter model inferred from direct measurement of in vitro stutter noise.

Raz O, Biezuner T, Spiro A, Amir S, Milo L, Titelman A, Onn A, Chapal-Ilani N, Tao L, Marx T, Feige U, Shapiro E.

Nucleic Acids Res. 2019 Mar 18;47(5):2436-2445. doi: 10.1093/nar/gky1318.

6.

Tumor-Infiltrating Lymphocytes-Location for Prognostic Evaluation.

Peled M, Onn A, Herbst RS.

Clin Cancer Res. 2019 Mar 1;25(5):1449-1451. doi: 10.1158/1078-0432.CCR-18-3803. Epub 2018 Dec 19.

PMID:
30567833
7.

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.

Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y.

Clin Cancer Res. 2018 Nov 15;24(22):5610-5621. doi: 10.1158/1078-0432.CCR-18-0450. Epub 2018 Jul 2.

PMID:
29967248
8.

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.

Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J; Israel Lung Cancer Group.

J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30.

PMID:
29723688
9.

Tattoo-Induced False-Positive FDG PET/CT Interpretation while Staging for Lung Cancer.

Marom EM, Ofek E, Bekker E, Onn A.

J Thorac Oncol. 2018 Apr;13(4):585-586. doi: 10.1016/j.jtho.2018.01.004. Epub 2018 Jan 31. No abstract available.

10.

Neo-adjuvant Chemo-Radiation to 60 Gray Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer Patients: Evaluation of Trimodality Strategy.

Appel S, Goldstein J, Perelman M, Rabin T, Urban D, Onn A, Shulimzon TR, Weiss I, Lieberman S, Marom EM, Golan N, Simansky D, Ben-Nun A, Lawrence YR, Bar J, Symon Z.

Isr Med Assoc J. 2017 Oct;19(10):614-619.

11.

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.

Shlomi D, Abud M, Liran O, Bar J, Gai-Mor N, Ilouze M, Onn A, Ben-Nun A, Haick H, Peled N.

J Thorac Oncol. 2017 Oct;12(10):1544-1551. doi: 10.1016/j.jtho.2017.06.073. Epub 2017 Jul 12.

12.

Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.

Shiran I, Heller E, Jessel S, Kamer I, Daniel-Meshulam I, Navon R, Urban D, Onn A, Bar J.

Clin Lung Cancer. 2017 May;18(3):316-323.e1. doi: 10.1016/j.cllc.2017.01.009. Epub 2017 Feb 2.

PMID:
28237243
13.

Hospital clones of methicillin-resistant Staphylococcus aureus are carried by medical students even before healthcare exposure.

Orlin I, Rokney A, Onn A, Glikman D, Peretz A.

Antimicrob Resist Infect Control. 2017 Jan 23;6:15. doi: 10.1186/s13756-017-0175-2. eCollection 2017.

14.

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.

Nardi-Agmon I, Abud-Hawa M, Liran O, Gai-Mor N, Ilouze M, Onn A, Bar J, Shlomi D, Haick H, Peled N.

J Thorac Oncol. 2016 Jun;11(6):827-37. doi: 10.1016/j.jtho.2016.02.017. Epub 2016 Mar 9.

15.

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Onn A, Uziely B, Peretz T.

Br J Cancer. 2016 Feb 16;114(4):469-76. doi: 10.1038/bjc.2016.7. Epub 2016 Jan 26.

16.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

17.

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y.

Oncogene. 2016 Jan 28;35(4):438-47. doi: 10.1038/onc.2015.93. Epub 2015 Apr 27.

PMID:
25915843
18.

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R.

Ann Oncol. 2015 Aug;26(8):1791-8. doi: 10.1093/annonc/mdv191. Epub 2015 Apr 23.

19.

Preferences for disclosure of disease related information among thoracic cancer patients.

Sella T, Botser D, Navon R, Biran H, Tenenbaum S, Urban D, Onn A, Bar J.

Lung Cancer. 2015 Apr;88(1):100-3. doi: 10.1016/j.lungcan.2015.01.021. Epub 2015 Jan 31.

PMID:
25682317
20.

Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.

Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y.

Semin Oncol. 2014 Oct;41 Suppl 6:S35-41. doi: 10.1053/j.seminoncol.2014.09.006. Epub 2014 Sep 8.

21.

EGFR mutation testing practice in advanced non-small cell lung cancer.

Bar J, Cyjon A, Flex D, Sorotsky H, Biran H, Dudnik J, Peylan-Ramu N, Peled N, Nechushtan H, Gips M, Katsnelson R, Rosenberg SK, Merimsky O, Onn A, Gottfried M.

Lung. 2014 Oct;192(5):759-63. doi: 10.1007/s00408-014-9604-7. Epub 2014 Jun 26.

PMID:
24964874
22.

Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA.

Clin Lung Cancer. 2014 Sep;15(5):379-86. doi: 10.1016/j.cllc.2014.04.002. Epub 2014 May 14.

23.

Establishing and sustaining a biorepository network in Israel: challenges and progress.

Cohen Y, Almog R, Onn A, Itzhaki-Alfia A, Meir K.

Biopreserv Biobank. 2013 Dec;11(6):331-8. doi: 10.1089/bio.2013.0046. Epub 2013 Nov 22.

PMID:
24835362
24.

Screening for lung cancer: time for large-scale screening by chest computed tomography.

Shlomi D, Ben-Avi R, Balmor GR, Onn A, Peled N.

Eur Respir J. 2014 Jul;44(1):217-38. doi: 10.1183/09031936.00164513. Epub 2014 Feb 13. Review.

25.

Angiogenesis inhibition and lung-cancer therapy.

Onn A, Bar J, Herbst RS.

Lancet Oncol. 2014 Feb;15(2):124-5. doi: 10.1016/S1470-2045(14)70010-5. No abstract available.

PMID:
24480554
26.

Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Perelman M, Ben Nun A, Simansky D, Yellin A, Urban D, Onn A.

Clin Lung Cancer. 2014 Mar;15(2):159-65. doi: 10.1016/j.cllc.2013.11.005. Epub 2013 Nov 14.

PMID:
24370118
27.

Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion.

Damianovich M, Hout Siloni G, Barshack I, Simansky DA, Kidron D, Dar E, Avivi C, Onn A.

Clin Lung Cancer. 2013 Nov;14(6):688-98. doi: 10.1016/j.cllc.2013.06.007. Epub 2013 Aug 6.

PMID:
23931900
28.

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study.

Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G.

Biomarkers. 2013 Sep;18(6):502-8. doi: 10.3109/1354750X.2013.816777. Epub 2013 Jul 29.

PMID:
23902289
29.

[Tissue repositories for research at Sheba Medical Center(SMC].

Cohen Y, Barshack I, Onn A.

Harefuah. 2013 Jun;152(6):319-22, 370, 369. Hebrew.

PMID:
23885461
30.

EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy.

Bar J, Urban D, Borshtein R, Nechushtan H, Onn A.

Chin Clin Oncol. 2013 Mar;2(1):2. doi: 10.3978/j.issn.2304-3865.2012.12.03. No abstract available.

31.

Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.

Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS.

J Thorac Oncol. 2013 Feb;8(2):140-6. doi: 10.1097/JTO.0b013e3182725ff9.

32.

Anti-angiogenic treatments in advanced NSCLC: back to the drawing board.

Bar J, Shiran I, Urban D, Agbarya A, Onn A.

J Thorac Dis. 2012 Dec;4(6):643-6. doi: 10.3978/j.issn.2072-1439.2012.10.11. No abstract available.

33.

Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma.

Urban D, Mishra M, Onn A, Dicker AP, Symon Z, Pfeffer MR, Lawrence YR.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):780-5. doi: 10.1016/j.ijrobp.2012.01.007. Epub 2012 Mar 13.

PMID:
22420965
34.

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.

Bar J, Onn A.

Clin Lung Cancer. 2012 Jul;13(4):267-79. doi: 10.1016/j.cllc.2011.09.001. Epub 2011 Dec 9.

PMID:
22154113
35.

Modeling the endoplasmic reticulum unfolded protein response.

Onn A, Ron D.

Nat Struct Mol Biol. 2010 Aug;17(8):924-5. doi: 10.1038/nsmb0810-924.

PMID:
20683476
36.

Chromosomal numerical aberrations in apparently normal oral mucosa of heavy smokers affected by lung cancer.

Shani T, Onn A, Kabha A, Ben-Dov I, Adam I, Amariglio N, Yahalom R, Rechavi G, Trakhtenbrot L, Hirshberg A.

Oral Oncol. 2010 Feb;46(2):96-9. doi: 10.1016/j.oraloncology.2009.10.010. Epub 2009 Dec 9.

PMID:
20004132
37.

Targeted drug delivery strategies to treat lung metastasis.

Bar J, Herbst RS, Onn A.

Expert Opin Drug Deliv. 2009 Oct;6(10):1003-16. doi: 10.1517/17425240903167926. Review.

PMID:
19663628
38.

Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, Onn A.

J Thorac Oncol. 2008 Apr;3(4):351-7. doi: 10.1097/JTO.0b013e318168c7e9.

39.

Combined anti-proliferative and anti-angiogenic strategies for cancer.

Bar J, Onn A.

Expert Opin Pharmacother. 2008 Apr;9(5):701-15. doi: 10.1517/14656566.9.5.701. Review.

PMID:
18345949
40.

Multitargeted inhibitors in lung cancer: new clinical data.

Bar J, Herbst RS, Onn A.

Clin Lung Cancer. 2008;9 Suppl 3:S92-9. doi: 10.3816/CLC.2008.s.014. Review.

PMID:
19419930
41.

Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.

Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS.

Mol Cancer Ther. 2007 Oct;6(10):2652-63. Epub 2007 Oct 3.

42.

Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer.

Jimenez CA, Mhatre AD, Martinez CH, Eapen GA, Onn A, Morice RC.

Chest. 2007 Nov;132(5):1584-90. Epub 2007 Sep 21.

PMID:
17890482
43.

Angiogenesis and lung cancer: implications for prognosis and treatment.

Onn A, Herbst RS.

Lancet Oncol. 2007 Jun;8(6):460-1. No abstract available.

PMID:
17540301
44.

Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients.

Gupta S, Jain A, Warneke CL, Gupta A, Shannon VR, Morice RC, Onn A, Jimenez CA, Bashoura L, Giralt SA, Dickey BF, Eapen GA.

Bone Marrow Transplant. 2007 Jul;40(1):71-8. Epub 2007 May 7.

PMID:
17483846
45.

BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.

Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK.

J Thorac Oncol. 2006 Nov;1(9 Suppl):S2-7. Erratum in: J Thorac Oncol. 2007 Jan;2(1):11. Kim, Kwok [corrected to Wong, Kwok-Kin].

46.

Pulmonary manifestations in patients with cutaneous T-cell lymphomas.

Baser S, Onn A, Lin E, Morice RC, Duvic M.

Cancer. 2007 Apr 15;109(8):1550-5.

47.

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.

48.

Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.

Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8.

49.

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.

Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ.

Expert Opin Investig Drugs. 2007 Feb;16(2):239-49. Review.

PMID:
17243944
50.

Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status.

Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Lin E, Morice RC.

Chest. 2006 Dec;130(6):1784-90.

PMID:
17166997

Supplemental Content

Support Center